Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 2,671 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Withdrawn Phase 2 Interventional

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

NCT02850874
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Adenocarcinoma
Interventions
Hyperthermic intraperitoneal chemotherapy, Open pancreaticoduodenectomy, Gemcitabine
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

RSV F Dose-Ranging Study in Women

NCT01960686
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Walnut Creek, California • Stockbridge, Georgia • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 2 Interventional Results available

Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer

NCT01439945
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Hot Flashes
Interventions
magnesium oxide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
283
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Aurora, Colorado + 192 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Nov 4, 2026, 5:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Technology Development for Physical Rehabilitation of Patients With Upper Extremity Motor Deficits (RePlay)

NCT03621969
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Physical exam and medical history, Assessments, Patient Instruction and use of Device (RePlay)
Other · Diagnostic Test · Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Addison, Texas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Nov 4, 2026, 5:59 PM EST
Terminated Phase 3 Interventional Results available

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

NCT03447769
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
21
States / cities
Fayetteville, Arkansas • Los Alamitos, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 2 Interventional

Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT04284657
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Pravastatin, sodium citrate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

NCT04570657
View directory record Official record
Conditions
Asthma
Interventions
MEDI3506, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Bakersfield, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 2 Interventional

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

NCT01083875
View directory record Official record
Conditions
Oral Mucositis
Interventions
amlexanox, Vehicle rinse
Drug
Lead sponsor
Access Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bakersfield, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Nov 4, 2026, 5:59 PM EST
Active, not recruiting Phase 3 Interventional

Pivotal Study of Voro Urologic Scaffold

NCT06873581
View directory record Official record
Conditions
Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Interventions
Voro Urologic Scaffold
Device
Lead sponsor
Levee Medical, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 4 Interventional Results available

Pectoralis and Serratus Muscle Blocks

NCT03743194
View directory record Official record
Conditions
Post Operative Pain Control
Interventions
Exparel 266 MG Per 20 ML Injection, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Nov 4, 2026, 5:59 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

NCT03787095
View directory record Official record
Conditions
HIV Infections
Interventions
Cemiplimab, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 2 Interventional Results available

Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel

NCT01637077
View directory record Official record
Conditions
Pain, Peripheral Neuropathy
Interventions
pregabalin, placebo, questionnaire administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Wichita, Kansas • Duluth, Minnesota • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Nov 4, 2026, 5:59 PM EST
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Nov 4, 2026, 5:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prevention Trial Assessing Paper-Tape in Endurance Distances II (Pre-TAPED II)

NCT01945112
View directory record Official record
Conditions
Blister of Foot
Interventions
Paper Tape
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Nov 4, 2026, 5:59 PM EST
Not yet recruiting Not applicable Interventional

Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma

NCT07869381
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II, Cutaneous Melanoma, Acral Melanoma
Interventions
Wide Local Excision
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 4, 2026, 5:59 PM EST
Not yet recruiting Not applicable Interventional

Multi-level Intervention to Successfully Transition to Adult Care for Survivors of Childhood and Adolescent Cancers: The BRIDGES-YAS! Study

NCT07915479
View directory record Official record
Conditions
Health Care Transition, Survivorship Care, Survivors of Childhood Cancer, Patient Navigation
Interventions
Structured Transition to PCP, Comparison Arm
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 26 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
3
States / cities
Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 4, 2026, 5:59 PM EST
Completed Not applicable Interventional Results available

Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome

NCT02640053
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Cryotherapy, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Urbana, Illinois • Grand Rapids, Michigan • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Nov 4, 2026, 5:59 PM EST
Terminated Phase 1Phase 2 Interventional

A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60

NCT02280395
View directory record Official record
Conditions
Postoperative Wound Infection-deep, Post Operative Wound Infection
Interventions
RUT058-60, Sterile saline for irrigation
Drug
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Mobile, Alabama • La Jolla, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Nov 4, 2026, 5:59 PM EST
Recruiting Phase 2 Interventional

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

NCT05830058
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 2 Interventional Results available

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

NCT00436826
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Interferon-beta (IFN-beta)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
21
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Nov 4, 2026, 5:59 PM EST
Completed Phase 2 Interventional Results available

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

NCT02905578
View directory record Official record
Conditions
Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms, Adenocarcinoma
Interventions
Gemcitabine, nab-paclitaxel, Pharmacological ascorbate
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 4, 2026, 5:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Community Influences Transitions in Youth Health (CITY) Health II - Center for the Study of Community Health

NCT04320186
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
Entertainment education, video
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 25 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Nov 4, 2026, 5:59 PM EST